Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
Case Report/Case Series
October 2015

Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy

Author Affiliations
  • 1Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut
JAMA Dermatol. 2015;151(10):1110-1112. doi:10.1001/jamadermatol.2015.1520
Abstract

Importance  Vitiligo is a common condition that is often emotionally devastating for patients. At present, no reliably effective treatments are available.

Observations  Recent advances in the understanding of the pathogenesis of vitiligo suggest that Janus kinase inhibitors may be a therapeutic option. We report a case of generalized vitiligo for which treatment with tofacitinib citrate, an oral Janus kinase 1/3 inhibitor, resulted in significant repigmentation.

Conclusions and Relevance  The results suggest that tofacitinib and other Janus kinase inhibitors may be effective in the treatment of vitiligo. Additional studies will be needed to confirm their efficacy and to explore their safety.

×